glp-1 agonist adverse effects Part 2 of a 3-Part Series; Medications for Weight Loss glp 1 agonist risks Peptide/GLP-1

GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats

It is available for in vitro research and laboratory use only, not for human or veterinary use

The significant burden of CKD and CVD in type 1 diabetes populations highlights the need to identify novel therapies with the potential for heart and kidney protection

Whilst great advancements have been made over the last century with regard to understanding the regulation of metabolic homeostasis which has yielded new therapeutic options for diseases such as T2D, it is unlikely that highly desirable more efficacious treatments will be developed for metabolic disorders until the complex systemic regulation of metabolic homeostasis becomes more intricately understood